NEVADA, Feb. 6 /PRNewswire-FirstCall/ - Alpaca Enterprises Ltd. today announced the acquisition of Neuroscience Therapy Corporation and the appointment of a new Director to the Board of Directors of the Company.
The Company would like to announce the appointment of Ralph Thomas, as Director by the Board of Directors.
Ralph H. Thomas is an accomplished leader in global marketing and business management, with an emphasis on the development of strategic marketing plans for the commercialization of new products. Mr. Thomas’ experience in new product development processes and program management is global in scope. His accomplishments include commercialization of multiple immunodiagnostic assays and integrated clinical chemistry analyzer system/reagents, as well as the development of product design requirements from a B2C projects. Ralph has over 24 years of experience in vitro diagnostics with such companies as Chiron Diagnostics, Instrumentation Laboratories and Bayer Diagnostics. Most recently, Ralph was responsible for revitalizing Bausch & Lomb’s Refractive Surgery business. This included the development of a sales and marketing strategy that was targeted at the top 300 ophthalmic surgeons who perform 80% of all LASIK surgeries. It also included the launch of a revolutionary new method for performing custom LASIK surgeries for surgeons and consumers, which was supported by TV advertising and a print campaign.
About Alpaca Enterprises Ltd.
Alpaca Enterprises Ltd. (Neuroscience Therapy Corporation) holds the license to a unique medical device used to effectively treat a variety of acute and chronic pain conditions.
Legal Notice Regarding Forward Looking Statements
The statements in this press release that relate to the Company’s expectations with regard to the future impact on the Company’s results are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results.
Alpaca Enterprises Ltd.
CONTACT: Raymond Johnson, Toll-Free 1-866-639-3900
